Guggenheim Reiterates Buy Rating on IDEAYA Biosciences, Inc. (IDYA)

Market Context

IDEAYA Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $32.36 with a market capitalization of $2.9B. The stock has declined 1.7% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for IDEAYA Biosciences, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for IDEAYA Biosciences, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 04, 2026	Guggenheim	Buy	N/A
Nov 04, 2026	Truist Securities	Buy	N/A
Nov 04, 2026	RBC Capital	Outperform	N/A
Nov 04, 2026	Wedbush	Outperform	N/A
Oct 16, 2026	William Blair	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View IDYA Stock Page